We hypothesize that the determinant of the development of MMR-deficient cells into hypermutated recurrent gliomas is that the large number of passenger mutations caused by TMZ plus MMR deficiency successfully activate a variety of carcinogenic pathways, rendering these subclones more resistant and invasive. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.